HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one

inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase

Also Known As:

S17834

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - 6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - 6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one: 5

Experts

1.	Cohen, Richard A: 3 articles (04/2012 - 08/2006)
2.	Hou, Xiuyun: 3 articles (04/2012 - 08/2006)
3.	Verbeuren, Tony J: 3 articles (04/2012 - 08/2006)
4.	Jiang, Bingbing: 2 articles (04/2011 - 08/2006)
5.	Wierzbicki, Michel: 2 articles (04/2011 - 08/2006)
6.	Xu, Shanqin: 2 articles (04/2011 - 08/2006)
7.	Zang, Mengwei: 2 articles (04/2011 - 08/2006)
8.	Calamaras, Timothy D: 1 article (04/2012)
9.	Colucci, Wilson S: 1 article (04/2012)
10.	Higuchi, Akiko: 1 article (04/2012)

Related Diseases

1.	Hypertension (High Blood Pressure) 07/01/2007 - "Other inhibitors, including diphenylene iodonium, aminoethyl benzenesulfono fluoride, S17834, PR39, protein kinase C inhibitors, and VAS2870, have shown promise in vitro, but their in vivo specificity, pharmacokinetics, and effectiveness in hypertension remains to be determined. "
2.	Atherosclerosis 10/01/2001 - "These results indicate that S17834 inhibits adhesion molecule expression and adherence of leukocytes to endothelial cells as well as aortic atherogenesis and that perhaps these effects can be explained by its ability to inhibit endogenous superoxide anion production." 10/01/2001 - "S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase." 04/06/2011 - "Hepatic activation of AMPK by the synthetic polyphenol S17834 protects against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in diet-induced insulin-resistant LDL receptor-deficient mice in part through phosphorylation of SREBP-1c Ser372 and suppression of SREBP-1c- and -2-dependent lipogenesis. "
3.	Hyperlipidemias (Hyperlipidemia) 08/01/2006 - "Furthermore, treatment of DMLDLR(-/-) mice with S17834 prevented the decrease in AMPK and ACC phosphorylation and the lipid accumulation in the liver, and it also inhibited hyperlipidemia and the acceleration of aortic lesion development. " 04/06/2011 - "Hepatic activation of AMPK by the synthetic polyphenol S17834 protects against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in diet-induced insulin-resistant LDL receptor-deficient mice in part through phosphorylation of SREBP-1c Ser372 and suppression of SREBP-1c- and -2-dependent lipogenesis. "
4.	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 04/10/2012 - "Treatment with S17834 or resveratrol prevented left ventricular hypertrophy and diastolic dysfunction. " 04/10/2012 - "Resveratrol and S17834 administered concurrently with a HFHS diet prevent the development of left ventricular hypertrophy, interstitial fibrosis, and diastolic dysfunction. "
5.	Hyperinsulinism (Hyperinsulinemia) 04/10/2012 - "For S17834, these beneficial effects were associated with decreases in oxidant-mediated protein modifications and hyperinsulinemia and increased plasma adiponectin. "

Related Drugs and Biologics

1.	Protein Kinase C
2.	Fluorides
3.	3- benzyl- 7- (2- benzoxazolyl)thio- 1,2,3- triazolo(4,5- d)pyrimidine
4.	diphenyleneiodonium
5.	Polyphenols
6.	Adiponectin
7.	Sterol Regulatory Element Binding Protein 1
8.	NADPH Oxidases (NAD(P)H oxidase)
9.	Oxidants (Oxidizing Agents)
10.	Superoxides (Superoxide)